<h1>National research body licenses indigenous multi-stage recombinant malaria vaccine to five companies for development and commercialization</h1> A national health research body licensed an indigenous multi-stage recombinant malaria vaccine to five commercial firms following an open expression-of-interest for transfer of technology to enable commercialization. The license grants rights to develop, manufacture and commercialize the vaccine, which has completed preclinical validation with affiliated research institutes and is described as stable at room temperature for over nine months and effective in preventing plasmodium falciparum infection and reducing transmission. The transaction followed a competitive selection process; regulatory approvals, manufacturing scale-up obligations, and post-licensing compliance and liability provisions are implied prerequisites for commercial rollout.